Epigenetics

Epigenetics is the control of gene expression without altering the DNA sequence, including DNA methylation, genomic imprinting, maternal effects, gene silencing, nucleolus dominant, dormant transposon activation, and RNA editing. In contrast to classical genetics, which focuses on the effects of gene sequences on biological functions, epigenetics focuses on the mechanisms by which these "epigenetic phenomena" are established and maintained.

Cat. No.	Product name
BP14175	SantacruzaMate A
BP14175	Santacruzamate A (CAY10683) is a potent and selective HDAC inhibitor.
BP14174	S2101
BP14174	S 2101 is an inhibitor of lysine-specific demethylase 1 (LSD1)(IC50 of 0.99 μM, Ki of 0.61 μM and Kinact/Ki of 4560 M/s).
BP14173	RVX-297
BP14173	RVX-297 is a BD2 selective inhibitor of BET bromodomains. RVX-297 preferentially binds to the BD2 domains of the BET bromodomain and Extra Terminal (BET) family of protein.
BP14172	Apabetalone
BP14172	RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.
BP14171	Rucaparib
BP14171	Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP.
BP14170	Rucaparib Phosphate
BP14170	Rucaparib is an inhibitor of PARP (Ki: 1.4 nM for PARP1) that is used in clinical therapy to sensitize cancer cells to chemotherapy.
BP14169	Rucaparib monocamsylate
BP14169	Rucaparib Camsylate is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains.
BP14168	RTS-V5
BP14168	RTS-V5 is a dual inhibitor of HDAC/proteasome (IC50s: 6.9, 18, 15, 0.27, 0.53 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, respectively).
BP14167	Ro 31-8220 Mesylate
BP14167	Ro 31-8220 is a pan-PKC inhibitor for PKC-α/βI/βII/γ/ε (IC50: 5/24/14/27/24 nM), and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.
BP14166	RN-1 dihydrochloride
BP14166	RN-1 dihydrochloride is an effective and selective irreversible inhibitor of lysine-specific demethylase 1 (LSD1, IC50 = 70 nM).
BP14165	RK-9123016
BP14165	RK-9123016 is a SIRT2 inhibitor. RK-9123016 increases the acetylation level of eukaryotic translation initiation factor 5A (eIF5A), a physiological substrate of SIRT2, and reduces cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression.
BP14164	RK-287107
BP14164	RK-287107 is an effective and specific inhibitor of tankyrase (IC50s: 14.3 and 10.6 nM for tankyrase-1 and tankyrase-2, respectively).
BP14163	Ricolinostat
BP14163	Ricolinostat is an orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity.
BP14162	RGFP966
BP14162	RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM, exhibits > 200-fold selectivity over other HDAC.
BP14161	RGFP966
BP14161	RGFP966 is an HDAC3 inhibitor (IC50: 0.08 μM) and does not affect other HDACs at concentrations up to 15 μM.
BP14160	RG2833
BP14160	RG2833 (RGFP109), a brain-penetrant HDAC inhibitor, is with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.
BP14159	RG108
BP14159	RG108 is an DNA methyltransferase inhibitor(IC50=115 nM).
BP14158	Resminostat
BP14158	Resminostat is an orally bioavailable inhibitor of histone deacetylases (HDACs) with potential antineoplastic activity.
BP14157	Resminostat hydrochloride
BP14157	Resminostat hydrochloride is an effective inhibitor of HDAC1/HDAC3/HDAC6 (IC50: 42.5/50.1/71.8 nM), respectively, and shows less potent activities against HDAC8 (IC50: 877 nM).
BP14156	Remodelin
BP14156	Remodelin is an effective and specific inhibitor of the acetyl-transferase protein NAT10.